Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chindex Agrees to Higher $24/Share Bid from Insiders

publication date: Apr 21, 2014
Chindex, which operates private hospitals and clinics in China, accepted a buy-out offer of $24 per share from company insiders, which values the company at $434 million. The latest offer tops a $23 per share bid by an unnamed suitor, which refused the board’s invitation to raise its offer. The insiders consist of Fosun Pharma, which already owns 17.5% of Chindex, the US private equity group TPG and Roberta Lipson, the company’s founder and CEO. Previously, TPG funded ShangPharma's go-private transaction. More details....

Stock Symbols: (NSDQ: CHDX) (SHA: 000196; HK: 2196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital